Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro
Abstract Background Ricin A chain (RTA) and Pokeweed antiviral proteins (PAPs) are plant-derived N-glycosidase ribosomal-inactivating proteins (RIPs) isolated from Ricinus communis and Phytolacca Americana respectively. This study was to investigate the potential production amenability and sub-toxic...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-08-01
|
Series: | BMC Biotechnology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12896-018-0458-6 |
id |
doaj-6b082df1389c48fa8484008bfa7ed90e |
---|---|
record_format |
Article |
spelling |
doaj-6b082df1389c48fa8484008bfa7ed90e2020-11-25T01:22:54ZengBMCBMC Biotechnology1472-67502018-08-0118111110.1186/s12896-018-0458-6Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitroYasser Hassan0Sherry Ogg1Hui Ge2Ophiuchus Medicine Inc.Johns Hopkins University, AAPAscentGene Inc.Abstract Background Ricin A chain (RTA) and Pokeweed antiviral proteins (PAPs) are plant-derived N-glycosidase ribosomal-inactivating proteins (RIPs) isolated from Ricinus communis and Phytolacca Americana respectively. This study was to investigate the potential production amenability and sub-toxic antiviral value of novel fusion proteins between RTA and PAPs (RTA-PAPs). In brief, RTA-Pokeweed antiviral protein isoform 1 from seeds (RTA-PAPS1) was produced in an E. coli in vivo expression system, purified from inclusion bodies using gel filtration chromatography and protein synthesis inhibitory activity assayed by comparison to the production of a control protein Luciferase. The antiviral activity of the RTA-PAPS1 against Hepatitis B virus (HBV) in HepAD38 cells was then determined using a dose response assay by quantifying supernatant HBV DNA compared to control virus infected HepAD38 cells. The cytotoxicity in HepAD38 cells was determined by measuring cell viability using a tetrazolium dye uptake assay. The fusion protein was further optimized using in silico tools, produced in an E. coli in vivo expression system, purified by a three-step process from soluble lysate and confirmed in a protein synthesis inhibition activity assay. Results Results showed that RTA-PAPS1 could effectively be recovered and purified from inclusion bodies. The refolded protein was bioactive with a 50% protein synthesis inhibitory concentration (IC50) of 0.06 nM (3.63 ng/ml). The results also showed that RTA-PAPS1 had a synergetic activity against HBV with a half-maximal response concentration value (EC50) of 0.03 nM (1.82 ng/ml) and a therapeutic index of > 21,818 with noticeable steric hindrance. Results also showed that the optimized protein ricin A chain mutant-Pokeweed antiviral protein isoform 1 from leaves (RTAM-PAP1) could be recovered and purified from soluble lysates with gain of function on protein synthesis inhibition activity, with an IC50 of 0.03 nM (1.82 ng/ml), and with minimal, if any, steric hindrance. Conclusions Collectively, our results demonstrate that RTA-PAPs are amenable to effective production and purification in native form, possess significant gain of function on protein synthesis inhibition and anti-HBV activities in vitro with a high therapeutic index and, thus, merit further development as potential potent antiviral agents against chronic HBV infection to be used as a standalone or in combination with existent therapies.http://link.springer.com/article/10.1186/s12896-018-0458-6Fusion proteinsRicinPokeweed antiviral proteinHepatitis B virusAntiviral agentRibosome-inactivating proteins |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yasser Hassan Sherry Ogg Hui Ge |
spellingShingle |
Yasser Hassan Sherry Ogg Hui Ge Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro BMC Biotechnology Fusion proteins Ricin Pokeweed antiviral protein Hepatitis B virus Antiviral agent Ribosome-inactivating proteins |
author_facet |
Yasser Hassan Sherry Ogg Hui Ge |
author_sort |
Yasser Hassan |
title |
Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro |
title_short |
Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro |
title_full |
Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro |
title_fullStr |
Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro |
title_full_unstemmed |
Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro |
title_sort |
expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (rta-paps) in escherichia coli and their inhibition of protein synthesis and of hepatitis b virus in vitro |
publisher |
BMC |
series |
BMC Biotechnology |
issn |
1472-6750 |
publishDate |
2018-08-01 |
description |
Abstract Background Ricin A chain (RTA) and Pokeweed antiviral proteins (PAPs) are plant-derived N-glycosidase ribosomal-inactivating proteins (RIPs) isolated from Ricinus communis and Phytolacca Americana respectively. This study was to investigate the potential production amenability and sub-toxic antiviral value of novel fusion proteins between RTA and PAPs (RTA-PAPs). In brief, RTA-Pokeweed antiviral protein isoform 1 from seeds (RTA-PAPS1) was produced in an E. coli in vivo expression system, purified from inclusion bodies using gel filtration chromatography and protein synthesis inhibitory activity assayed by comparison to the production of a control protein Luciferase. The antiviral activity of the RTA-PAPS1 against Hepatitis B virus (HBV) in HepAD38 cells was then determined using a dose response assay by quantifying supernatant HBV DNA compared to control virus infected HepAD38 cells. The cytotoxicity in HepAD38 cells was determined by measuring cell viability using a tetrazolium dye uptake assay. The fusion protein was further optimized using in silico tools, produced in an E. coli in vivo expression system, purified by a three-step process from soluble lysate and confirmed in a protein synthesis inhibition activity assay. Results Results showed that RTA-PAPS1 could effectively be recovered and purified from inclusion bodies. The refolded protein was bioactive with a 50% protein synthesis inhibitory concentration (IC50) of 0.06 nM (3.63 ng/ml). The results also showed that RTA-PAPS1 had a synergetic activity against HBV with a half-maximal response concentration value (EC50) of 0.03 nM (1.82 ng/ml) and a therapeutic index of > 21,818 with noticeable steric hindrance. Results also showed that the optimized protein ricin A chain mutant-Pokeweed antiviral protein isoform 1 from leaves (RTAM-PAP1) could be recovered and purified from soluble lysates with gain of function on protein synthesis inhibition activity, with an IC50 of 0.03 nM (1.82 ng/ml), and with minimal, if any, steric hindrance. Conclusions Collectively, our results demonstrate that RTA-PAPs are amenable to effective production and purification in native form, possess significant gain of function on protein synthesis inhibition and anti-HBV activities in vitro with a high therapeutic index and, thus, merit further development as potential potent antiviral agents against chronic HBV infection to be used as a standalone or in combination with existent therapies. |
topic |
Fusion proteins Ricin Pokeweed antiviral protein Hepatitis B virus Antiviral agent Ribosome-inactivating proteins |
url |
http://link.springer.com/article/10.1186/s12896-018-0458-6 |
work_keys_str_mv |
AT yasserhassan expressionofnovelfusionantiviralproteinsricinachainpokeweedantiviralproteinsrtapapsinescherichiacoliandtheirinhibitionofproteinsynthesisandofhepatitisbvirusinvitro AT sherryogg expressionofnovelfusionantiviralproteinsricinachainpokeweedantiviralproteinsrtapapsinescherichiacoliandtheirinhibitionofproteinsynthesisandofhepatitisbvirusinvitro AT huige expressionofnovelfusionantiviralproteinsricinachainpokeweedantiviralproteinsrtapapsinescherichiacoliandtheirinhibitionofproteinsynthesisandofhepatitisbvirusinvitro |
_version_ |
1725124732803612672 |